BRMS1 Polyclonal Antibody, FITC Conjugated
Product Specifications
Background
Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.
Synonyms
Breast cancer metastasis-suppressor 1; BRMS1
Gene ID
25855
Swiss Prot
Q9HCU9
Cellular Locus
Cytoplasm, Nucleus
Host
Rabbit
Cross Reactivity
Human
Immunogen
151-246/246
Target
BRMS1
Clonality
Polyclonal
Isotype
IgG
Conjugation
FITC
Source
KLH conjugated synthetic peptide derived from human BRMS-1
Applications
WB, IF (IHC-P), IF (IHC-F), IF (ICC)
Purification
Purified by Protein A.
Excitation Emission
494nm/518nm
Concentration
1µg/µl
Dilution
WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
25855
Predicted Cross Reactivity
Mouse, Rat
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0428206 1.0 µg DNA
CEACAMP7 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
Sign In for Pricing
View Details